Abstract: A TRV-type turbine casing includes inner and outer annular shrouds that extend one inside the other and about the same axis and are connected together by arms. A tool for disassembling and moving the casing has a lower carriage for moving the tool, and an upper plate to be attached to the turbine casing. The plate is supported by the carriage and includes first members that cooperate with a first annular flange of one of the shrouds to support the casing and axially immobilize the casing relative to the tool. The plate further includes second members that cooperate with a second annular flange of the other shroud in order to prevent and/or guide the rotation of the casing about the axis.

Abstract: The present disclosure provides a novel treatment for addiction disorders, particularly opioid addiction. More specifically, the present disclosure provides a treatment for opioid addiction comprising a combination use of any one or more of SCFAs in combination with one or more carnitines, providing effective depletion of microbiome in certain brain regions. A diagnosis method for the progress of the addiction treatment is also provided.

Abstract: The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.

Abstract: The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.

Abstract: The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.

Abstract: Methods, devices, control modules, and computer readable media are provided for managing acute and chronic pain in subjects. More specifically, a method is provided for reducing pain in a subject that includes delivering to the subject a series of stimuli consisting of both painful and non-painful stimuli. A portion of each of the painful and the non-painful stimuli is delivered to the subject during a systolic phase of the subject's cardiac cycle and the remaining portion of each of the painful and the non-painful stimuli is delivered during a diastolic phase of the subject's cardiac cycle.

Abstract: Methods, devices, control modules, and computer readable media are provided for managing acute and chronic pain in subjects. More specifically, a method is provided for reducing pain in a subject that includes delivering to the subject a series of stimuli consisting of both painful and non-painful stimuli. A portion of each of the painful and the non-painful stimuli is delivered to the subject during a systolic phase of the subject's cardiac cycle and the remaining portion of each of the painful and the non-painful stimuli is delivered during a diastolic phase of the subject's cardiac cycle.

Abstract: An enzyme having a NMDA antagonist activity and/or an anticholinergic activity, wherein the enzyme is selected from the group including phosphotriesterases and phosphotriesterases derivatives. A method for treating a disease, disorder or condition of the central nervous system in a subject, wherein the method includes administering to the subject the enzyme is also described.